Compare HBNC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBNC | SDGR |
|---|---|---|
| Founded | 1873 | 1990 |
| Country | United States | United States |
| Employees | N/A | 850 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 925.8M |
| IPO Year | 1995 | 2020 |
| Metric | HBNC | SDGR |
|---|---|---|
| Price | $18.28 | $12.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $21.00 | $21.00 |
| AVG Volume (30 Days) | 263.8K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | N/A | $0.76 |
| Revenue Next Year | $5.52 | $4.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $14.38 | $10.95 |
| 52 Week High | $19.07 | $27.63 |
| Indicator | HBNC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 54.08 |
| Support Level | $15.69 | $11.08 |
| Resistance Level | $18.72 | $13.33 |
| Average True Range (ATR) | 0.49 | 0.71 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 82.85 | 54.59 |
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.